UK markets closed
  • FTSE 100

    -45.71 (-0.79%)
  • FTSE 250

    -234.21 (-1.31%)
  • AIM

    -3.60 (-0.37%)

    +0.0025 (+0.22%)

    +0.0040 (+0.31%)

    +316.15 (+3.14%)
  • CMC Crypto 200

    +8.46 (+3.24%)
  • S&P 500

    -2.45 (-0.07%)
  • DOW

    -132.36 (-0.48%)

    +1.03 (+2.67%)

    +4.20 (+0.22%)
  • NIKKEI 225

    -8.54 (-0.04%)

    -131.59 (-0.53%)
  • DAX

    -83.14 (-0.68%)
  • CAC 40

    -67.48 (-1.40%)

Anti-Hypertensive Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery

·4-min read

Major players in the anti-hypertensive drugs market are Merck & Co. Inc. , Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd. and Pfizer, Inc. The global anti-hypertensive drugs market is expected to decline from $26.

New York, Sept. 24, 2020 (GLOBE NEWSWIRE) -- announces the release of the report "Anti-Hypertensive Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery" -
1 billion in 2019 to $23.5 billion in 2020 at a compound annual growth rate (CAGR) of -9.7%. The decline is mainly because of the lockdown measures due to the COVID-19 outbreak. The decrease in the number of cardiac surgeries due to re-scheduling of surgeries, cancellations and no-show by patients, decrease in consultations due to restrictions by government and health authorities to provide only emergency services, and less heart disease admissions contribute to this decline. However, the decline is not significant as research showed that the covid patients developed cardiovascular complications, and therefore health authorities advised covid and non-covid cardiac patients to continue the use of CVD drugs. The market is then expected to recover and grow at a CAGR of 2.8% from 2021 and reach $27.7 billion in 2023.

The anti-hypertensive drugs market consists of sales of anti-hypertensive drugs and related services. These drugs are re used to prevent heart failure, kidney failure and acute stroke induced by hypertension. Some of the major anti-hypertensive drugs include Diuretics, Angiotensin-converting enzyme (ACE) inhibitors, and Angiotensin II receptor antagonists.

North America was the largest region in the anti-hypertensive drugs market. This region is expected to remain the largest during the next five years. The anti-hypertensive drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The US Food and Drug Administration (FDA) issued a guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. US FDA expects to see a reduction in adverse effects for combinations that include doses below each drugs’ maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their programme, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on the fixed-combination drugs.

Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the Anti-Hypertensive Drugs market. Firstly, most of the people in developing nations neglect their health-checkups and are not aware about the existing hypertension condition in them until they detect extreme symptoms Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, in the year 2016, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of antihypertensive market.

Of late, there has been rise in use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of a hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When we combine the two drugs with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well.

Sedentary lifestyle is a major driver for the growth of the anti-hypertensive drugs market. Consumption of junk food, lack of proper healthy and balanced diet, lack of proper sleep due to irregular workshifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed of hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001